Background and Purpose: TA3090 (Clentiazem) has been shown to have cerebrovascular protective properties in three experimental studies. An in vivo investigation was undertaken to determine its effects on pial arteries and cerebral blood flow and its therapeutic value in transient focal cerebral ischemia.
The Effect of a New Calcium Antagonist, TA3090 (Clentiazem), on Background and Purpose: TA3090 (Clentiazem) has been shown to have cerebrovascular protective properties in three experimental studies. An in vivo investigation was undertaken to determine its effects on pial arteries and cerebral blood flow and its therapeutic value in transient focal cerebral ischemia.
Methods: This experiment was divided into two protocols. In the first, 200 or 400 ug/kg per hour TA3090 was administered continuously for 3 hours in cats without ischemic insult (n=6 for each group). The effects on pial arteries and cerebral blood flow were estimated. In the second protocol, 400 ,ug/kg per hour TA3090 (treated group, n=14) or physiological saline (control group, n=10) was administered 5 minutes before 1 hour of middle cerebral aretery occlusion in cats. The effects on the pial arteries and cerebral blood flow were observed continuously, followed by autoradiography for a quantitative measurement of cerebral blood flow 5 hours after middle cerebral artery recirculation. The volumes of the cerebral edema and infarct were estimated by planimetry from cerebral preparations made for histological examination.
Results: Pial arteries dilated by up to approximately 10%v in the 400-,ug group and 3% in the 200-p£g group 30 minutes after administration of TA3090. Increases in cerebral blood flow of about 10%o in the 400-,g group and 2% in the 200 -1Lg group were demonstrated with laser Doppler flowmetry. In the second protocol, dilatation of pial arteries was significantly smaller during and after the ischemic insult in the treated group compared with the control group (p<0.01). Cerebral blood flow decreased less significantly during ischemia (p<0.01 at the end of ischemia) and increased less significantly after ischemia (p<0.01 at the end) in the treated group compared with the control group. Autoradiography showed a more remarkable increase in cerebral blood flow due to luxury perfusion in the cerebral cortex, which was mainly perfused by the middle cerebral artery on the affected side in the control group (p<0.01). Cerebral blood flow in the cerebral cortex, thalamus, and caudate nucleus on the contralateral side of the treated group increased by about 20% more than that of the control group (p<0.05). Cerebral edema and infarction were much smaller in the treated group than in the control group (p<0.01).
Conclusions: 1) TA3090 dilates pial arteries and increases cerebral blood flow in normal brain regions in a dose-response fashion; 2) in ischemic regions compared with those in untreated animals, TA3090 results in a lesser reduction of cerebral blood flow during ischemia and in a lesser degree of hyperemia during reperfusion; 3) TA3090 is associated with less pial artery dilatation during ischemia, presumably due to improved collateral flow; and 4) the improved hemodynamic state with TA3090 is associated with significant reduction of cerebral edema and infarct size. studies have also demonstrated the drug's selectivity for rabbit cerebral arteries, which surpasses those of diltiazem and nifedipine.3 Furthermore, experimental studies have shown a beneficial effect of TA3090 on the reduction of infarct size in a rabbit model of middle cerebral artery (MCA) occlusion. 4 The effect of TA3090 on the cerebral pial arteries and its beneficial effect on cerebral damage in transient focal ischemia were studied because it may be possible to prolong the temporary clipping time during neurosurgery and obtain beneficial effects in the treatment of an extremely acute stage of cerebral infarction or a late angiospasm after subarachnoid hemorrhage.
Materials and Methods Surgical Preparation
Experiments with TA3090 (Tanabe Seiyaku Co., Ltd., Osaka, Japan) were performed in adult cats of either sex (2.5-3.5 kg body weight) that were not subjected to fasting. In all animals, blood glucose was measured (Glucoster, Miles Inc.) soon after anesthesia was induced. Although the glucose levels were approximately 300 mg/dL, they were corrected to 100-120 mg/dL by the intravenous administration of regular insulin before the start of the experiment. Anesthesia was induced by intravenous administration of thiopental (30 The left middle cerebral artery (MCA) was exposed through the transorbital approach after excentation of the orbit and enlargement of the optic foramen toward the superior orbital fissure with a dental drill. The dura mater was opened, and the arachnoid membrane was incised to expose the main trunk of the MCA for temporary clipping. A microsurgical clip (Zen clip, Ohwa, Inc., Tokyo) was used for the temporary clipping.
Assessment of Pial Arterial Diameter Changes
The diameters of the pial arteries were observed scope and videotape recorder were used for the continuous observation and assessment of changes in caliber.
The images of pial arteries in the cranial window were recorded on tape and analyzed later using a threechannel videoangiometer (model C316, Hamamatsu Photonics, Hamamatsu, Japan) and a multichannel recorder (WT645G, Nihon Kohden, Inc., Tokyo). To determine the preservation of the CO2 reactivity of the pial arteries, 2% bicarbonate gas was inspired for 2 minutes, followed by the confirmation of pial artery dilatation before the start of the experiment in each cat.
Measurement of Cerebral Blood Flow
A laser Doppler flowmeter (LDF) (model AIF21, Advance, Inc., Tokyo) was set on the window for continuous measurement of blood flow. At the end of the experiment in protocol 2, the regional cerebral blood flow (rCBF) was determined according to the method of Sakurada et al.5 A 250-,Ci dose of
[14C]iodoantipyrine dissolved in Ringer's solution was administered intravenously for 1 minute by means of a ramp infusion (pump model 22, Harvard Apparatus South Natick, Mass.). At the end of the infusion, a tourniquet was placed around the cat's neck and inflated during the intravenous injection of 10 mL of a saturated potassium solution to immediately stop the cerebral blood circulation. After removal of the skull bone and dura mater, the brain was lifted at its frontal part to dissect the brain stem and connecting nerves. The cerebellum was separated by incision, and the brain was carefully removed from the remaining skull, avoiding pressure on the cortex.
The brains were immersed in liquid isopentylhydrocupreine, chilled to -70°C, and stored in a freezer at -70°C until sectioning. Coronal Upon occlusion of the MCA, cessation of pial artery pulsation and a marked slowing of pial venous blood flow were confirmed through the window. A marked drop in blood flow in the LDF was observed whenever adequate ischemia occurred in the area of the MCA. If these findings were not observed even after reclipping, the animal was excluded from the study because of inadequate ischemia.
A total of 14 cats in the TA3090 group and 10 cats in the control group could be evaluated effectively.
Results
There were no significant changes in arterial Paco2, Pao2, hematocrit, serum potassium, serum sodium, or pH in any of the groups during experimental periods.
Protocol 1
The ICP increased 10% after 45 minutes compared with the resting value and remained at the 7.5% level 90 (Figure 1) .
The pial arteries dilatated gradually after the start of TA3090 administration and reached maximum value 40 minutes later; the diameter eventually decreased slightly, but the arteries remained in a dilated state (8±+3% in the 400 jig/kg per hour group, p<0.01; 3±2.5% in the 200 jug/kg per hour group) (Figure 2 ).
The CBF measured by LDF through the cranial window increased to 10% and remained in such a state until the end of the experiment, although the CBF increased to 12% transiently 2 hours after the administration of 400 pg/kg per hour TA3090. This increase in CBF was significantly higher than that in the 200-,gdose group (Figure 3 in the TA3090-treated group than in the control group 3 hours after the start of the experiment (p<0.05), the value was within the threshold of the autoregulation. Regarding the ICP, there were no significant differences at any time between both groups (Table 1) .
Changes in pial arterial diameter. The pial arteries of the control group were observed through the cranial window. The arteries dilated by 65-70% during MCA clipping and remained dilated after clip removal (i.e., 30% in the first 3 hours and more in the last 2 hours). On the other hand, in the TA3090 group they dilated by 8% soon after administration of TA3090 and by 50% after MCA occlusion. After reopening of the MCA, the pial arteries returned to a state of 25% dilation and remained unchanged until the end of the experiment. Diameter changes of the pial arteries in the TA3090 group were significantly less than those in the control group during and after occlusion of the MCA (Figure 4) .
Changes in cerebral blood flow measured by laser Doppler flowmeter. In the control group, rCBF decreased to -90% of the resting value and gradually increased to -80%. The CBF increased to 40% immediately after the clip was removed from the MCA, then dropped by 15%, and eventually increased to 40%. The CBF increased 6% over resting value after the start of the TA3090 infusion, dropped to -90% after MCA occlusion, then gradually recovered to -60%. After reopening of the MCA, the rCBF increased to 20% over resting value, then gradually decreased and remained at 10% ( Figure 5 ).
Regional cerebral blood flow measured by autoradiography. There were remarkable differences in rCBF between the control group and the TA3090 group 5 hours after reperfusion of the MCA (Table 2 ). In the control group, the rCBF in the suprasylvian gyrus, ectosylvian gyrus, sylvian gyrus, and head of the caudate nucleus of the affected side increased markedly and reached a level three times greater than that in the contralateral side in six animals in the control group. The differences in the rCBF in the corpus callosum, internal capsule, thalamus, and hippocampus between the affected and unaffected sides were not statistically significant. On the other hand, although the rCBF in the ectosylvian gyrus and the head of the caudate nucleus in the TA3090 group increased more significantly (p<0.01) in the affected side than in the contralateral side, the increase in rCBF was not as remarkable compared with that in the control group. Furthermore, as in the control group, the rCBF in the other areas was almost the same as that in the contralateral side. The continuous administration of TA3090 resulted in an approximately 20% increase in rCBF over that of the control group in the cerebral cortex, caudate nucleus, and thalamus of the nonaffected side ( Figure 6 ).
Histopathologic findings. The extent of cerebral edema and infarction was determined from histological findings. In the control group, cerebral edema was approximately 47.4+7.8% (mean±SE) of the hemisphere, and cerebral infarct was 41.9±5.9%. In the TA3090 group, cerebral edema was 25.5±4.3% and cerebral infarction 18.4+3.1%. The extent of both cerebral edema and infarction was significantly larger in the control group than in the TA3090 group (p<0.01) (Figure 7 ).
Discussion
Calcium Antagonistic Activities of TA3090 The recently synthetized 1,5-benzothiazepine derivative TA3090 has potent and long-lasting antihypertensive7 and vasodilatory2 actions. Although diltiazem (another 1,5-benzothiazepine derivative) is an effective calcium antagonist, the calcium antagonistic activity of TA3090 is more potent and exhibits a higher degree of cerebrovascular selectivity against agonist-and potassium-induced contractions than that of diltiazem.8-'2 Moreover, the concentration of TA3090 required to affect the cerebral vasculature is much lower than that required to depress the action of the heart, and the concentration is achieved at doses that do not significantly lower arterial blood pressure in rabbits.3 In this experiment with cats, the action of TA3090 on the heart and arterial blood pressure was much weaker than that for cerebral arterial diameter changes.
Microvascular Observations
In protocol 1, the pial arteries dilated more significantly (p<0.01) in animals that received 400 ,g/kg per hour TA3090 than in those receiving 200 ,ug/kg per hour. This result suggests that TA3090 gives rise to a dose-dependent dilatation of the pial arteries like that of nimodipine.13 In this experiment, pial arterial dilatation in the treated group appeared to correlate with decrease of MABP and increase of ICP secondary to TA3090 infusion. However, the degree of the pial dilatation was out of proportion to the MABP decrease, and the rCBF also increased despite the blood pressure change. These In the present study, there was a large discrepancy between the rCBF measured quantitatively by autoradiography and that estimated from changes in blood flow measured continuously by LDF. This discrepancy could have resulted from the decreased estimation of cortical surface blood flow because LDF was performed through a cover glass over the cranial window.
In the autoradiographic study, the rCBF in the cortex and basal ganglia of the hemisphere contralateral to that with MCA occlusion increased more significantly in the treated group than in the control group. On the other hand, the rCBF in the affected area of the hemisphere with MCA occlusion increased remarkably 5 hours after recirculation of the MCA in the control group because of postischemic hyperperfusion25-27; this phenomenon confirms Lassen's concept of "luxury perfusion."728 In the cats treated with TA3090, postischemic hyperperfusion was not so prominent as in the control group. Moreover, the fact that rCBF during recirculation was lower in the TA3090-treated group than in the control group may be secondary to the decreased blood pressure in the former group, although this difference reached statistical significance only at 2 hours after recirculation.
These 
